Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last kr287.80 DKK
Change Today -6.40 / -2.18%
Volume 432.2K
As of 11:04 AM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

novozymes a/s-b shares (NZYMB) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/5/15 - kr363.80
52 Week Low
10/16/14 - kr221.80
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NOVOZYMES A/S-B SHARES (NZYMB)

Related News

No related news articles were found.

novozymes a/s-b shares (NZYMB) Related Businessweek News

No Related Businessweek News Found

novozymes a/s-b shares (NZYMB) Details

Novozymes A/S produces and sells industrial enzymes, microorganisms, and biopolymers worldwide. The company offers solutions for the agriculture industry, including enzymes to enhance digestibility and nutritional value of animal feed; microbial solutions to maintain water quality, limit risks of disease, and enhance yields in aquaculture; and microbial-based biofertility, biocontrol, and bioyield enhancer products to naturally produce healthier crops and enhance yields. It also provides a portfolio of enzymes for application in biofuel production; recombinant products and technologies to the medical device and drug delivery market; and food and beverages enzymes for applications in baking, brewing, dairy, distilling, flavor enhancement, food specialties, health and nutrition, juice, meat processing, oils and fats, starch, and wine industries. In addition, the company offers household care enzyme and microbial agents for use in cleaning solutions, dishwashing, and laundry; enzymes for biopreparation, degreasing, and re-bating of leather; enzymes for pulp and paper production processes, such as bleach boosting, deinking, drainage enhancement, effluent control, pitch control, refining, slime control, starch modification, and stickies control; enzymatic solutions for processing textiles; and microbial solutions for biological wastewater treatment. Novozymes A/S has a strategic alliance with Monsanto Company to discover, develop, and sell microbial solutions for farmers. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark.

6,536 Employees
Last Reported Date: 08/6/15
Founded in 1925

novozymes a/s-b shares (NZYMB) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: kr9.7M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: kr5.9M
Executive Vice President of Business Operatio...
Total Annual Compensation: kr5.4M
Executive Vice President of Research & Develo...
Total Annual Compensation: kr6.0M
Executive Vice President of Supply Operations
Total Annual Compensation: kr5.9M
Compensation as of Fiscal Year 2014.

novozymes a/s-b shares (NZYMB) Key Developments

Novozymes A/S Reports Unaudited Group Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Revises Earnings Guidance for the Year 2015

Novozymes A/S reported unaudited group earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported revenue of DKK 3,449 million compared to DKK 3,061 million a year ago. EBITDA was DKK 3,061 million compared to DKK 1,011 million a year ago. EBIT was DKK 930 million compared to DKK 787 million a year ago. Profit before tax was DKK 880 million compared to DKK 767 million a year ago. Net profit attributable to company was DKK 682 million compared to DKK 591 million a year ago. Diluted earnings per share were DKK 2.20 against DKK 1.87 a year ago. For the six months, the company reported revenue of DKK 7,028 million compared to DKK 6,094 million a year ago. EBITDA was DKK 2,421 million compared to DKK 2,178 million a year ago. EBIT was DKK 1,909 million compared to DKK 1,710 million a year ago. Profit before tax was DKK 1,792 million compared to DKK 1,669 million a year ago. Net profit attributable to company was DKK 1,388 million compared to DKK 1,284 million a year ago. Diluted earnings per share were DKK 4.47 against DKK 4.05 a year ago. Return on equity was 24.7% compared to 23.5% a year ago. Net interest-bearing debt as on June 30, 2015 was DKK 62 million compared to positive DKK 961 million as of June 30, 2014. Cash flow from operating activities was DKK 1,987 million compared to DKK 3,204 million a year ago. Purchase of property, plant and equipment was DKK 370 million against DKK 206 million a year ago. Purchase of intangible assets was DKK 7 million. The 2015 outlook for organic sales growth is revised to 4% to 7% (7% to 9% at previous guidance). Sales in DKK are now expected to increase by 13% to 16% (16% to 18% at previous guidance). The expectation for EBIT margin is increased to 27% to 28% (27% at previous guidance). Net profit growth is expected to be 11% to 13%, unchanged from prior guidance. Free cash flow before acquisitions is expected to be DKK 2,500 million to DKK 2,700 million, unchanged from prior guidance. EBIT growth is maintained at 15% to 17%.

Novozymes A/S, H1 2015 Earnings Call, Aug 06, 2015

Novozymes A/S, H1 2015 Earnings Call, Aug 06, 2015

Novozymes A/S Presents at Jefferies 11th Annual Industrials Conference, Aug-10-2015

Novozymes A/S Presents at Jefferies 11th Annual Industrials Conference, Aug-10-2015 . Venue: Grand Hyatt, 109 E. 42nd Street, New York, New York, United States.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NZYMB:DC kr287.80 DKK -6.40

NZYMB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Chr Hansen Holding A/S kr342.10 DKK -7.40
Ebro Foods SA €17.86 EUR -0.23
EMS-Chemie Holding AG SFr.421.00 CHF -10.50
Kerry Group PLC €63.78 EUR -1.32
Tate & Lyle PLC 541.50 GBp -6.00
View Industry Companies

Industry Analysis


Industry Average

Valuation NZYMB Industry Range
Price/Earnings 34.4x
Price/Sales 6.6x
Price/Book 7.9x
Price/Cash Flow 28.6x
TEV/Sales 5.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVOZYMES A/S-B SHARES, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at